Literature DB >> 23794788

Primary and Reversible Pisa Syndrome in Juvenile Normal Pressure Hydrocephalus.

Fidias E Leon-Sarmiento1, Gustavo Pradilla, Maria Del Rosario Zambrano.   

Abstract

OBJECTIVE: To report a case of Pisa syndrome in a patient with idiopathic normal pressure hydrocephalus, who had never been exposed to psychotropic medications.
METHODS: A 26 years-old, Colombian, male patient, was referred because he had cognitive abnormalities, gait disturbances and urinary incontinence. This patient also displayed pleurothotonos. Neurofunctional evaluation of sensory and motor integration at peripheral and central nervous system levels were done.
RESULTS: Pisa syndrome disappeared after spinal tap drainage with further gait, balance and behavioral improvement. A brainstem-thalamocortical deregulation of the central sensory and motor programming, due to the chaotic enlargement of brain ventricles was thought to be the pathophysiological mechanism underlying this case.
CONCLUSION: NPH must not be longer considered as an exclusive geriatric disorder. Further, uncommon movement disorders may appear with this disorder, which should be carefully approached to avoid iatrogenic and deleterious pharmacological interventions.

Entities:  

Year:  2013        PMID: 23794788      PMCID: PMC3686565          DOI: 10.1111/j.1601-5215.2012.00657.x

Source DB:  PubMed          Journal:  Acta Neuropsychiatr        ISSN: 0924-2708            Impact factor:   3.403


  20 in total

1.  Primary anticholinergic-responsive Pisa syndrome.

Authors:  K F Bhattacharya; I Giannakikou; N Munroe; K R Chaudhuri
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

2.  In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus.

Authors:  Yasuomi Ouchi; Teiji Nakayama; Toshihiko Kanno; Etsuji Yoshikawa; Tomomi Shinke; Tatsuo Torizuka
Journal:  J Cereb Blood Flow Metab       Date:  2006-08-16       Impact factor: 6.200

3.  Electroconvulsive therapy-associated Pisa syndrome in clozapine treatment.

Authors:  Wen-Kuei Lee; I-Shin Shiah; Chun-Yen Chen; Tsai-Li Lin; Lih-Jong Shen
Journal:  Psychiatry Clin Neurosci       Date:  2008-12       Impact factor: 5.188

Review 4.  Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

Authors:  Toshihito Suzuki; Hisashi Matsuzaka
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Instability of R3 response of the blink reflex in patients with HAM/TSP.

Authors:  F E Leon-S; K Arimura; Y Sonoda; Y Arimura; M Osame
Journal:  Funct Neurol       Date:  1994 Jul-Aug

6.  The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics.

Authors:  S Hakim; R D Adams
Journal:  J Neurol Sci       Date:  1965 Jul-Aug       Impact factor: 3.181

Review 7.  Chronic ("normal pressure") hydrocephalus in childhood and adolescence. A review of 16 cases and reappraisal of the syndrome.

Authors:  P Bret; J Chazal
Journal:  Childs Nerv Syst       Date:  1995-12       Impact factor: 1.475

Review 8.  INPH and Parkinson disease: differentiation by levodopa response.

Authors:  Takashi Morishita; Kelly D Foote; Michael S Okun
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

9.  Striatonigral degeneration.

Authors:  A E Kan
Journal:  Pathology       Date:  1978-01       Impact factor: 5.306

10.  Motor cortical hyperexcitability in idiopathic scoliosis: could focal dystonia be a subclinical etiological factor?

Authors:  Julio Doménech; José María Tormos; Carlos Barrios; Alvaro Pascual-Leone
Journal:  Eur Spine J       Date:  2009-12-24       Impact factor: 3.134

View more
  2 in total

1.  Reversible Parkinsonism and Pisa Syndrome in Juvenile Normal Pressure Hydrocephalus.

Authors:  Sanjay Pandey
Journal:  Mov Disord Clin Pract       Date:  2014-12-30

2.  Reversible Pisa syndrome associated to subdural haematoma: case-report.

Authors:  Pasquale Marchione; Aldo Spallone; Marcella Valente; Cristiano Giannone; Floriana De Angelis; Giuseppe Meco
Journal:  BMC Neurol       Date:  2014-08-14       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.